MARAVAI LIFESCIENCES HOLDINGS, INC.
About MARAVAI LIFESCIENCES HOLDINGS, INC.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $185.7M
- Net income
- -$130.8M
- Total assets
- $770.6M
- Market cap
- $740.5M
- Gross margin
- 18.3%
- Operating margin
- -115.9%
- Net margin
- -124.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $185.7M
- Cost of revenue
- $151.8M
- Gross profit
- $34.0M
- Operating expenses
- $249.3M
- Operating income
- -$215.3M
- Income tax
- -$4.2M
- Net income
- -$230.8M
- EPS (basic)
- $-0.90
- EPS (diluted)
- $-0.90
Balance sheet
- Total assets
- $770.6M
- Current assets
- $296.3M
- Total liabilities
- $397.9M
- Current liabilities
- $44.9M
- Shareholders’ equity
- $372.7M
Cash flow
- Operating cash flow
- -$57.6M
- Investing cash flow
- -$31.4M
- Financing cash flow
- -$16.5M
- Net cash flow
- -$105.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $740.5M
- EPS (diluted)
- $-0.9
- Shares outstanding
- 146.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 20, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $130.8M in FY2025.
- Revenue declined 77% from FY2021 to FY2025.
- Gross margin of 18.3%, net margin -124.2%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MARAVAI LIFESCIENCES HOLDINGS, INC..
Write a review
News about MARAVAI LIFESCIENCES HOLDINGS, INC.
News & sentiment via Polygon.io
